CIITA

Last updated
CIITA
Identifiers
Aliases CIITA , C2TA, CIITAIV, MHC2TA, NLRA, class II, major histocompatibility complex, transactivator, class II major histocompatibility complex transactivator
External IDs OMIM: 600005 MGI: 108445 HomoloGene: 207 GeneCards: CIITA
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001243760
NM_001243761
NM_007575
NM_001302618
NM_001302619

Contents

RefSeq (protein)

NP_001230689
NP_001230690
NP_001289547
NP_001289548
NP_031601

Location (UCSC) Chr 16: 10.87 – 10.94 Mb Chr 16: 10.3 – 10.35 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

CIITA is a human gene which encodes a protein called the class II, major histocompatibility complex, transactivator. [5] Mutations in this gene are responsible for the bare lymphocyte syndrome in which the immune system is severely compromised and cannot effectively fight infection. [5] Chromosomal rearrangement of CIITA is involved in the pathogenesis of Hodgkin lymphoma and primary mediastinal B cell lymphoma. [6]

Function

CIITA mRNA can only be detected in human leukocyte antigen (HLA) system class II-positive cell lines and tissues. This highly restricted tissue distribution suggests that expression of HLA class II genes is to a large extent under the control of CIITA. [7] However, CIITA does not appear to directly bind to DNA. [7] Instead CIITA functions through activation of the transcription factor RFX5. [8] Hence CIITA is classified as a transcriptional coactivator.

The CIITA protein contains an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. [9] The protein uses GTP binding to facilitate its own transport into the nucleus. [10] Once in the nucleus, the protein acts as a positive regulator of class II major histocompatibility complex gene transcription, and is often referred to as the "master control factor" for the expression of these genes. [11] [12]

CIITA expression is induced by interferon gamma, possibly assisted by other signals. [13] MHC II expression in intestinal epithelial cells is upregulated under inflammation. [13]

Interactions

CIITA has been shown to interact with:

See also

Related Research Articles

<span class="mw-page-title-main">Major histocompatibility complex</span> Cell surface proteins, part of the acquired immune system

The major histocompatibility complex (MHC) is a large locus on vertebrate DNA containing a set of closely linked polymorphic genes that code for cell surface proteins essential for the adaptive immune system. These cell surface proteins are called MHC molecules.

A class II gene is a type of gene that codes for a protein. Class II genes are transcribed by RNAP II.

<span class="mw-page-title-main">Bare lymphocyte syndrome type II</span> Medical condition

Bare lymphocyte syndrome type II is a rare recessive genetic condition in which a group of genes called major histocompatibility complex class II are not expressed. The result is that the immune system is severely compromised and cannot effectively fight infection.

Bare lymphocyte syndrome is a condition caused by mutations in certain genes of the major histocompatibility complex or involved with the processing and presentation of MHC molecules. It is a form of severe combined immunodeficiency.

<span class="mw-page-title-main">MHC class II</span> Protein of the immune system

MHC Class II molecules are a class of major histocompatibility complex (MHC) molecules normally found only on professional antigen-presenting cells such as dendritic cells, mononuclear phagocytes, some endothelial cells, thymic epithelial cells, and B cells. These cells are important in initiating immune responses.

<span class="mw-page-title-main">NFYB</span> Protein-coding gene in the species Homo sapiens

Nuclear transcription factor Y subunit beta is a protein that in humans is encoded by the NFYB gene.

<span class="mw-page-title-main">HLA-F</span>

HLA class I histocompatibility antigen, alpha chain F is a protein that in humans is encoded by the HLA-F gene. It is an empty intracellular molecule that encodes a non-classical heavy chain anchored to the membrane and forming a heterodimer with a β-2 microglobulin light chain. It belongs to the HLA class I heavy chain paralogues that separate from most of the HLA heavy chains. HLA-F is localized in the endoplasmic reticulum and Golgi apparatus, and is also unique in the sense that it exhibits few polymorphisms in the human population relative to the other HLA genes; however, there have been found different isoforms from numerous transcript variants found for the HLA-F gene. Its pathways include INF-gamma signaling and CDK-mediated phosphorylation and removal of the Saccharomycescerevisiae Cdc6 protein, which is crucial for functional DNA replication.

<span class="mw-page-title-main">HLA-DMB</span>

HLA class II histocompatibility antigen, DM beta chain is a protein that in humans is encoded by the HLA-DMB gene.

<span class="mw-page-title-main">RFX1</span> Protein-coding gene in the species Homo sapiens

MHC class II regulatory factor RFX1 is a protein that, in humans, is encoded by the RFX1 gene located on the short arm of chromosome 19.

<span class="mw-page-title-main">RFX5</span> Protein-coding gene in the species Homo sapiens

DNA-binding protein RFX5 is a protein that in humans is encoded by the RFX5 gene.

<span class="mw-page-title-main">Lymphocyte-activation gene 3</span>

Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. LAG3, which was discovered in 1990 and was designated CD223 after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, is a cell surface molecule with diverse biologic effects on T cell function. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right.

<span class="mw-page-title-main">RFXANK</span> Protein-coding gene in the species Homo sapiens

DNA-binding protein RFXANK is a protein that in humans is encoded by the RFXANK gene.

<span class="mw-page-title-main">RFXAP</span>

Regulatory factor X-associated protein is a protein that in humans is encoded by the RFXAP gene.

<span class="mw-page-title-main">RFX2</span> Protein-coding gene in the species Homo sapiens

DNA-binding protein RFX2 is a protein that in humans is encoded by the RFX2 gene.

<span class="mw-page-title-main">RFX4</span> Protein-coding gene in the species Homo sapiens

Transcription factor RFX4 is a protein that in humans is encoded by the RFX4 gene.

<span class="mw-page-title-main">ZBTB32</span> Protein-coding gene in the species Homo sapiens

Zinc finger and BTB domain-containing protein 32 is a protein that in humans is encoded by the 1960 bp ZBTB32 gene. The 52 kDa protein is a transcriptional repressor and the gene is expressed in T and B cells upon activation, but also significantly in testis cells. It is a member of the Poxviruses and Zinc-finger (POZ) and Krüppel (POK) family of proteins, and was identified in multiple screens involving either immune cell tumorigenesis or immune cell development.

<span class="mw-page-title-main">HLA-DQB2</span>

HLA class II histocompatibility antigen, DX beta chain is a protein that in humans is encoded by the HLA-DQB2 gene.

<span class="mw-page-title-main">NFX1</span> Protein-coding gene in the species Homo sapiens

Transcriptional repressor NF-X1 is a protein that in humans is encoded by the NFX1 gene.

<span class="mw-page-title-main">RFX3</span> Protein-coding gene in the species Homo sapiens

Transcription factor RFX3 is a protein that in humans is encoded by the RFX3 gene.

Zinc finger, X-linked, duplicated family member C (ZXDC) is a human CIITA-binding protein involved in the activation of major histocompatibility complex (MHC) class I and II. For binding to occur, ZXDC must form an oligomeric complex with another copy of itself or with ZXDA, a related protein. ZXDC is activated by sumoylation, a post-translational modification.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000179583 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000022504 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. 1 2 Steimle V, Otten LA, Zufferey M, Mach B (Oct 1993). "Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)". Cell. 75 (1): 135–46. doi:10.1016/S0092-8674(05)80090-X. PMID   8402893. S2CID   30276144.
  6. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD (Mar 2011). "MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers". Nature. 471 (7338): 377–81. Bibcode:2011Natur.471..377S. doi:10.1038/nature09754. PMC   3902849 . PMID   21368758.
  7. 1 2 Mach B, Steimle V, Reith W (Apr 1994). "MHC class II-deficient combined immunodeficiency: a disease of gene regulation". Immunological Reviews. 138 (1): 207–21. doi:10.1111/j.1600-065X.1994.tb00853.x. PMID   8070816. S2CID   28869787.
  8. 1 2 Scholl T, Mahanta SK, Strominger JL (Jun 1997). "Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5". Proceedings of the National Academy of Sciences of the United States of America. 94 (12): 6330–4. Bibcode:1997PNAS...94.6330S. doi: 10.1073/pnas.94.12.6330 . PMC   21049 . PMID   9177217.
  9. Raval A, Howcroft TK, Weissman JD, Kirshner S, Zhu XS, Yokoyama K, Ting J, Singer DS (Jan 2001). "Transcriptional coactivator, CIITA, is an acetyltransferase that bypasses a promoter requirement for TAF(II)250". Molecular Cell. 7 (1): 105–15. doi: 10.1016/S1097-2765(01)00159-9 . PMID   11172716.
  10. Harton JA, Cressman DE, Chin KC, Der CJ, Ting JP (Aug 1999). "GTP binding by class II transactivator: role in nuclear import". Science. 285 (5432): 1402–5. doi:10.1126/science.285.5432.1402. PMID   10464099.
  11. Harton JA, Ting JP (Sep 2000). "Class II transactivator: mastering the art of major histocompatibility complex expression". Molecular and Cellular Biology. 20 (17): 6185–94. doi:10.1128/MCB.20.17.6185-6194.2000. PMC   86093 . PMID   10938095.
  12. LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W (Jun 2004). "Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes". European Journal of Immunology. 34 (6): 1513–25. doi:10.1002/eji.200424964. PMID   15162420. S2CID   21226976.
  13. 1 2 Heuberger C, Pott J, Maloy KJ (2021). "Why do intestinal epithelial cells express MHC class II?". Immunology . 162 (4): 357–367. doi:10.1111/imm.13270. PMC   7968399 . PMID   32966619.
  14. 1 2 Voong LN, Slater AR, Kratovac S, Cressman DE (Apr 2008). "Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator". The Journal of Biological Chemistry. 283 (14): 9031–9. doi: 10.1074/jbc.M706487200 . PMC   2431044 . PMID   18245089.
  15. Tzortzakaki E, Spilianakis C, Zika E, Kretsovali A, Papamatheakis J (Dec 2003). "Steroid receptor coactivator 1 links the steroid and interferon gamma response pathways". Molecular Endocrinology. 17 (12): 2509–18. doi: 10.1210/me.2002-0439 . PMID   12933903.
  16. 1 2 Hake SB, Masternak K, Kammerbauer C, Janzen C, Reith W, Steimle V (Oct 2000). "CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation". Molecular and Cellular Biology. 20 (20): 7716–25. doi:10.1128/mcb.20.20.7716-7725.2000. PMC   86349 . PMID   11003667.
  17. Nekrep N, Geyer M, Jabrane-Ferrat N, Peterlin BM (Aug 2001). "Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome". Molecular and Cellular Biology. 21 (16): 5566–76. doi:10.1128/MCB.21.16.5566-5576.2001. PMC   87278 . PMID   11463838.
  18. Raval A, Weissman JD, Howcroft TK, Singer DS (Jan 2003). "The GTP-binding domain of class II transactivator regulates its nuclear export". Journal of Immunology. 170 (2): 922–30. doi: 10.4049/jimmunol.170.2.922 . PMID   12517958.
  19. Al-Kandari W, Jambunathan S, Navalgund V, Koneni R, Freer M, Parimi N, Mudhasani R, Fontes JD (Jan 2007). "ZXDC, a novel zinc finger protein that binds CIITA and activates MHC gene transcription". Molecular Immunology. 44 (4): 311–21. doi:10.1016/j.molimm.2006.02.029. PMC   1624858 . PMID   16600381.
  20. Al-Kandari W, Koneni R, Navalgund V, Aleksandrova A, Jambunathan S, Fontes JD (Jun 2007). "The zinc finger proteins ZXDA and ZXDC form a complex that binds CIITA and regulates MHC II gene transcription". Journal of Molecular Biology. 369 (5): 1175–87. doi:10.1016/j.jmb.2007.04.033. PMC   1963517 . PMID   17493635.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.